Hematoporphyrin derivative photoradiation therapy in managing nevoid basal-cell carcinoma syndrome. A preliminary report.
Hematoporphyrin derivative (HpD) is a photodynamically active dye that is preferentially retained by malignant tissues and initiates a cytotoxic reaction when exposed to red light. Normal tissues adjacent to a tumor retain HpD to a lesser degree and are thus spared damage from the light-induced reaction. We describe the treatment of 40 basal-cell carcinomas in three patients with nevoid basal-cell carcinoma syndrome. All treated lesions showed disappearance of clinically apparent tumor within four to six weeks, and there was no damage to surrounding skin. Thirty-three lesions (82.5%) showed complete response on biopsy findings, while seven showed residual tumor cells. The recurrence rate was 10.8%, with the follow-up ranging from 12 to 14 months. Tumor response was related to the total light dose delivered and the size and location of the tumor.
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001478:Basal Cell Nevus Syndrome / Q000601:surgery / Q000628:therapy*; D002280:Basal Cell Carcinoma / Q000628:therapy*; D005500:Follow-Up Studies; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000008:administration & dosage*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010789:Phototherapy / Q000379:methods*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000601:surgery / Q000628:therapy*; D013997:Time Factors
D000970:Antineoplastic Agents; D006415:Hematoporphyrins; D011838:Radiation-Sensitizing Agents; D017324:Hematoporphyrin Derivative